Compare GBX & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GBX | BHVN |
|---|---|---|
| Founded | 1974 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 1996 | 2022 |
| Metric | GBX | BHVN |
|---|---|---|
| Price | $52.35 | $8.38 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $49.00 | $28.85 |
| AVG Volume (30 Days) | 205.9K | ★ 1.9M |
| Earning Date | 04-07-2026 | 03-02-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | ★ 28.02 | 26.08 |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $3,240,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.64 | N/A |
| P/E Ratio | $44.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.77 | $7.48 |
| 52 Week High | $59.19 | $31.18 |
| Indicator | GBX | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 44.71 | 26.55 |
| Support Level | $44.64 | $7.48 |
| Resistance Level | $54.15 | $15.66 |
| Average True Range (ATR) | 1.41 | 0.61 |
| MACD | -0.41 | -0.14 |
| Stochastic Oscillator | 39.02 | 4.37 |
Greenbrier Companies Inc supplies equipment and services to international freight transportation markets, designing and marketing freight railcars in North America, Europe, and Brazil through subsidiaries and joint ventures. It provides railcar wheel services, parts, maintenance, and conversion services in North America. The company owns a lease fleet sourced mainly from its manufacturing operations and offers railcar management, regulatory compliance, and leasing services to railroads and owners. It operates two segments: Manufacturing and Leasing & Fleet Management, with the majority of revenue from Manufacturing. The company operates in the U.S. and internationally, with the majority of revenue from the U.S. market.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.